Niva Bupa Health Insurance Company Limited — Investor Meet, 06-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Niva Bupa's H1 FY26 saw GWP rise 23% to INR3,983 Cr, with PAT doubling to INR132 Cr and combined ratio improving to 103.1%. Management noted a significant demand boost from 0% GST, driving over 50% retail growth and higher ticket sizes in October. GST benefits were passed to distributors, anticipating volume growth to offset commission changes; no immediate price hikes planned. Retail loss ratio was stable, while group loss ratio rose due to mix, cushioned by expense reduction. The company is investing in distribution, AI, and new products like ReAssure 3.0, focusing on "growth with profit" and health ecosystem expansion. Solvency is robust at 2.85x, with a mid-to-high teens ROE target by FY29. The outlook remains confident on the health insurance sector's long-term potential.